Jupiter Neurosciences, Inc. (JUNS) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Jupiter Neurosciences reported revenue of $21,796. Net income was -$8.6M (a -39662.8% net margin), or -$18.75 per diluted share. Gross margin was 80.6% and operating margin was -40873.2%. Operating activities generated -$5.4M of cash. At fiscal year end, Jupiter Neurosciences held $5.6M in total assets against $7.4M in total liabilities.
Open the full interactive Jupiter Neurosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Jupiter Neurosciences Key Stats
| Share Price | $3.36 |
|---|---|
| Market Cap | $1.9M |
| 52-Week Range | $2.42 – $127.50 |
| Shares Outstanding | 557,567 (basic, 2026 Q2) |
Jupiter Neurosciences Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | — | $21,796 |
| Cost of Goods Sold | — | $4,231 |
| Gross Profit | — | $17,565 |
| Operating Income | -$3.1M | -$8.9M |
| Pre-Tax Income | -$2.4M | -$8.6M |
| Net Income | -$2.4M | -$8.6M |
| Diluted EPS | -$6.00 | -$18.75 |
Jupiter Neurosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | — | $18,652 | $24,245 |
| Net Income | -$2.3M | -$2.6M | -$2.1M | -$2.3M |
| Diluted EPS | -$5.25 | -$0.07 | -$4.50 | -$4.08 |
Jupiter Neurosciences Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Current Assets | $4.7M | $4.8M |
| Total Assets | $6.2M | $5.6M |
| Current Liabilities | $2.0M | $7.4M |
| Total Liabilities | $2.0M | $7.4M |
| Shareholders' Equity | $4.2M | -$1.8M |
Jupiter Neurosciences Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$3.9M | -$5.4M |
| Cash From Financing | $7.7M | $5.4M |
Figures from Jupiter Neurosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Jupiter Neurosciences financials page for every line item.
Jupiter Neurosciences Company Profile
| Ticker | JUNS |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Jupiter, Florida |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001679628 |
Frequently Asked Questions
What was Jupiter Neurosciences' revenue in fiscal 2025?
Jupiter Neurosciences (JUNS) reported revenue of $21,796 for fiscal 2025.
What was Jupiter Neurosciences' net income in fiscal 2025?
Jupiter Neurosciences reported net income of -$8.6M for fiscal 2025.
What was Jupiter Neurosciences' earnings per share (EPS) in fiscal 2025?
Jupiter Neurosciences' diluted EPS was -$18.75 for fiscal 2025 (adjusted for any later stock splits).
What was Jupiter Neurosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Jupiter Neurosciences reported revenue of $24,245.
How many shares of Jupiter Neurosciences are outstanding?
Jupiter Neurosciences reported a weighted average of 557,567 basic shares outstanding in 2026 Q2.
What is Jupiter Neurosciences' market cap?
Based on its latest closing price, Jupiter Neurosciences (JUNS) has a market capitalization of about $1.9M.
When does Jupiter Neurosciences' fiscal year end?
Jupiter Neurosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Jupiter Neurosciences headquartered?
Jupiter Neurosciences lists its business address in Jupiter, Florida in its SEC filings.